At their heights, Denmark’s corporate champions seemed untouchable. Novo Nordisk A/S, long known mostly as an insulin maker, was Europe’s most valuable company last year, after riding a surge of demand for Ozempic and Wegovy.

Denmark's economy remains robust despite job cuts at Novo Nordisk , the finance minister told Reuters on Wednesday, dismissing concerns that the pharmaceutical company's financial troubles could further impact the country’s economic outlook.